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Prediction accuracy of sub-stage classification varies with different staging
methods of breast-cancer. In this Master’s thesis we investigate whether there
are differences in the performance of machine learning models across different
stages in two different staging systems with three different sets of RNA_Seq
data for predicting the sub-stage of breast-cancer.  
We applied Support Vector Machine method to classify the sub-stage of Surveil-
lance, epidemiology and End Results and Tumor, Node and Metastasis staging
system. We carried out tests to see whether the model performance differs in
both the staging systems. We also used three different data sets with prior fea-
ture selection and investigated the performance of the model in both staging
systems with different combinations of sub-stages. To make the performance re-
sult more accurate we used cross-validation with performance metric accuracy,
sensitivity and specificity. In order to ensure the classifiers` ability of prediction
we used three performance metric precisions, recall and F1 score. Finally, we
compared the results between the two staging systems and investigated
whether protein coding or non-coding RNA gives a better performance. We ap-
plied the principle component analysis to reduce the dimensionality and investi-
gate the performance. Our results show that micro-RNAs give a better classifi-
cation in both staging systems. 
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11. INTRODUCTION
Cancer is not a single disease but rather a group of diseases. Cancer cells grow inside
the body involving abnormal growth of cells when genes deny to let some of the cells to
die. As a result the cells are growing and forming tumor that turns into cancer in the hu-
man body. Breast cancer is the second most common cancer type after skin cancer in
women in the United States. Approximately 1 in 11 women is developing the malig-
nancy and 1 in 30 is dying from the disease [14]. Both men and women can have beast
cancer but it is rare in men. There are many types of breast cancers, among which the
most common one is called Breast Invasive Carcinoma (BRCA) [1]. This cancer grows
from the ductal gland and spreads all over the breast and in later stage it spreads to other
parts of the body. Breast cancer can be diagnosed by X-ray, blood test or other patholog-
ical tests. Many researchers are focusing on the gene based analysis breast cancer classi -
fication [2,21,22,19]. Cancer prediction and prognosis using machine learning algorithm
is not novel in the cancer research area. More than 1500 papers have been published to
identify, classify and prognoses cancer using machine learning [3]. Artificial Neural
Network (ANN) and the state of art technique have been used in cancer prediction and
prognosis for the last 20 years [4-6]. Those researches were mostly based on clinical
laboratory data such as patients cancer cell image samples, ultra sound data or other fac -
tor of cancer such ER, relapse etc. as input to the system and the output determines
whether a person has cancer and also determines the factor causing cancer. The primary
goals of cancer prediction and prognosis is different from detection and diagnosis [3]. 
Many cancer predictions have been performed on the basis of subtype classification,
cancer or not cancer patient classification or survivability analysis [9-11].  All of these
research outcomes are based on the patients’ clinical information.  The researchers fo-
cused on the patients’ age, sex, race, color, smoking habit (in the case of lung cancer),
Estrogen, Progesterone receptor or HER2 as a key factor (in the case of breast cancer).
The research outcome reveals that the key factors which cause the risk of a person de-
veloping breast cancer are ER+, PR+ or HER2.  Also it shows the probability of sur-
vival after the positive diagnosis. In fact cancer prognosis involved different subsets of
2biomarkers and multiple clinical factors including the general health, the family history
and the age of the patient. Typically the histological (cell-based), clinical and population
based information needs to be integrated with the help of an attending physician to
come up with a reliable prognosis. Prognostic and predicting breast-cancer or other can-
cer macro-scale factors including hormone receptor, family history, age, sex habit or en -
vironmental effects (uv radiation, radon-induced) [9] are not enough to make a robust
prediction. Basically, what is needed is some very specific molecular details about the
tumor or the patients` genetic information [13] such as micro-scale factors to be able to
give a robust prediction of cancer.     
The rapid growth of human cancer genome databases [36] allows researchers to predict
cancer more robustly. The last 10 years many researchers have proved that DNA micro
array can predict breast cancer better and more accurately than clinical data which in
turn helps the physicians to offer a more efficient treatment [16]. About 90% of the
breast cancer is always due to the abnormality in the genes and only 5%  to 10% gene
abnormality is inherited from families [15]. A study of breast tumor samples [17] shows
that breast tumor samples can be classified according to DNA microarray gene expres -
sion. Hierarchical clustering was used to classify on the basis of similarity and expres-
sion. 
Several researchers have found treasure in statistical analysis of microarray profile [18]
and showed the gene signature that is associated with breast cancer. The author used
principle component analysis (PCA) to sample the data and performed the famous hy-
pothesis test to find the association of the random signature with breast cancer. Signifi -
cant performance has been shown by using Affymetrix data with 70 gene signatures
[19]. 
The comparison of breast cancer molecular subtype prediction has been done in [22].
The authors analyzed previous researches, thirty-six published samples (5715) and five
published classifiers. It has been noticed in the article that the three-gene Subtype Clas-
sification Model (SCM) gives a significantly better performance than the others. The
SCM model worked with micro array data and the author used three bio markers from
the group of genes that are closely related to the molecular subtypes of the breast cancer.
The SCM applied the gaussian mixture model to predict the class levels of the genes .
The authors of [22] show that statistically the SCM method with three key genes gives a
3better performance. Hierarchical clustering model is another method which has been ap-
plied by many researches to predict subtype classification [17].         
A recent discovery of the powerful next generation sequencing (RNA_Seq) drew the at -
tention of researchers to investigate the class prediction and the prognosis of cancer.
Monitoring the RNA_seq expression and the transcriptome analysis can detect and give
the prognosis of cancer accordingly. The RNA_seq can also be used as a risk probability
factor in patients` genome. It can also determine the variant of expression in the cancer
cell. Recently micro-RNA plays the key role in metastatic cancer diagnosis [20]. Up to
now more than 2000 miRNAs have been identified, among which some of the sets of
miRNA play a basic role of signature in disease states. Those miRANs are called circu-
lating RNAs as they can circulate over the blood in the blood vessel. These miRNAs are
responsible for growing the cells. Several researchers claim that a few group of miRNA
are sufficient enough to classify the lymph-node based subtype of cancer [21]. Their re -
sults show that these genes are more deferentially expressed in the high risk breast can-
cer patients than in the low risk breast cancer patients.  Micro RNA is a small-non-pro-
tein-coding RNA that can act as the function of negative gene control . Recent research
shows that they can control hundreds of genes. Gene mutation and mis-expression of
certain miRNAs can cause different types of advanced level cancers in the human body.
Finding the signature genes in metastasis cancer with the help of using statistical analy-
sis has been done in [19,20,21,23]. These studies show micro-RNA and lncRNA in ex-
pression level plays a significant role in the metastasis breast cancer . The authors of
[23] used cox regression model and kaplan-meire analysis using ROC as performance
metric to classify sub-stages of breast-cancer and to identify bio markers. The author
claims that three lncRNA (CAT104, LINC01234, and STXBP5-AS1) predicts metasta-
sis breast-cancer with very good AUC and good sensitivity and specificity. They used
TNM system as different class level of breast-cancer. A few researchers show that miR-
139, miR-486 and miR-21 are the key genes for developing metastasis breast cancer
[21].        
In fact RNA_Seq gene data analysis has become more and more interesting to re -
searchers as it helps in finding biomarkers and also for predicting the subtypes of can -
cer. Long sequence RNA and small sequence RNA both have potential influence in the
progression to the advanced stage of cancer.  The differentially expressed RNA, com-
4bining with noncoding RNA and miRNA can be a cause of the progression of cancer in
human body.    
52. THEORETICAL BACKGROUND
In this section we will discuss the background knowledge that is crucial to understand
the breast cancer data analysis. At first we will discuss the are a of biology where our
analysis method has been implemented. After that we will continue with the machine
learning method that was used in our analysis such as the principal component analysis
and the support vector machine. At last we will briefly explain the machine learning li-
brary libsvm used in R programing language and will finish the section with the gene
ontology which we used in our study.   
2.1  RNA
Ribonucleic acid (RNA) is one of the three major biological macromolecules that are
necessary for all forms of life. It was believed for many years that RNA plays only three
major roles in the cell- the roles as a DNA prototype (mRNA), as a coupler between ge-
netic code and a protein building block and as a structural component of ribosome [26].
In the area of the genomic analysis many researchers dealing with RNA sequences are
working with two types of RNAs: protein coding RNAs ie. simply RNAs and non- cod-
ing RNAs, for instance micro-RNAs and lnc-RNAs.  Protein coding RNAs are those
genes which encode proteins and non–coding RNA are the ones that do not encode pro-
teins. The non-coding RNA is also known as the junk DNA. Many researchers identi-
fied a large number (5446) of human lnc-RNAs [26]. Small non-coding RNAs and mi -
croRNA are short, 18-22bp nucleotides [27,28]. Micro RNAs regulate gene expression
often as gene silencers.
6Figure 2.1.1  RNA extraction from chromosome[27].
2.2  RNA_Seq
RNA_Seq means using sequencing platforms such as Illumina [35]. It produces millions
of short reads of cDNA sequence at low cost.  RNA_Seq is a technique for NextSeq
which enables rapid profiling and deep sequencing of whole transcriptome. The advan-
tage of RNA_Seq over Gene expression array is – it does not require prior knowledge of
transcriptome, provides quantitative and qualitative transcriptome analysis, better speci -
ficity, sequence and variant information [29]. 
A population of RNA fragmented, such as poly (A+) is converted to a library of cDNA
with adapters in both ends (From figure 1-EST library with adapters). Each molecule is
then sequenced to a high throughput manner and afterwards it obtains a short sequence
read.
7Figure 2.2.1 RNA_Seq formation[27]. 
2.3  Micro RNA
Micro RNA was first discovered in 1993. MicroRNAs (miRNAs) are small (10-20 bp)
regulatory RNAs in humans and play a key role in cancer invasive [24]. They play the
key role in directing mRNA and regulating protein binding with RNAs. Each miRNA
can target more than 100 protein coding RNAs. Over expression of miRNA can cause
various types of cancers such as breast cancer, lung cancer or abdominal cancer. Circu -
lating miRNAs have also been discovered in peripheral blood circulation and are also
identified in the higher stage of cancer. Most probably miRNAs have been the most ex-
tensively studied the last few years. These short nucleotide non coding RNAs regulate
cellular transcriptome and proteome by destabilizing mRNA. Recently the miRNAs are
being chosen as a good biomarker for different types of diseases including cancer be-
8cause they are stable in the blood fluid of the human body and can be measured with
high sensitivity since they are amplifiable.
These small noncoding RNAs (miRNAs) can be used as the therapeutic treatment for
many diseases including the Alzheimer disease. In one research the miR-206 antagomir
increased the brain derived neurotrophic factor levels and improved the memory func-
tion in rats with Alzheimer. Not only miRNA but also mRNA or other protein together
with miRNA can cause the progressing stages of some cancers. RNA is involved in
communicating intercellular functionalities in several steps [25]:
 1. RNA can carry information in a simple and efficient way. For example mRNA
is involved in the coding of proteins.
 2. It can coordinate cellular activity in a fundamental and essential manner.  For
instance miRNA regulates transcriptome and proteome in a cellular level.
A cell can transport miRNA to different cells called recipient cells where miRNA can
function the same way.     
2.4  Breast Cancer Sub-stages
There are many different systems of breast cancer sub-stage classification. In this thesis
only two systems will be described. 
2.4.1  TNM  Staging System 
The most widely used tool to determine the stages of breast cancer is TNM staging sys-
tem [39]. Staging is a way to determine where the cancer cell is located and how far it
has spread all over the body. The abbreviation TNM comes from three terms: Tumor,
Node and Metastasis.
In the TNM system, “T” stands for Tumor, T plus a number or letter is used to denote
whether a tumor is identified or not in the patient`s body and determines how big it is.
Tx means that tumor is primarily identified in the body, while T0 means that there is no
tumor in the body. T1, T2, T3 and T4 determines the size of the tumor. 
9The “N” in the TNM system stands for the lymph node. The lymph nodes may contain
the cancer cells at different parts of the body.  N plus x or 0 indicates whether the cancer
cells are present and N plus a number with the value of 1 to 3 shows that which part of
the body the lymph nodes with the cancer cells are located. Nx means that it  cannot be
evaluated whether the lymph node contains cancer cells, N0 means that there is no can-
cer in the lymph node. N1-N3 can be subcategorized and the category given determines
where the cancer cells are located in the lymph node. 
Metastasis or in short “M” determines whether the cancer has spread to other parts of
the body. M plus x, 0 or 1 determines whether the cancer has spread to other parts of the
body. M0 means that it has not spread, Mx means that it cannot be evaluated and M1
means that cancer has already spread to other organs of the body. A fter examining these
three values the doctors can identify the stage of the breast cancer. There are nine stages
of breast cancer from 0 to IV, such as stage 0, stage IA, stage IB, stage IIA, stage IIB,
stage IIIA, stage IIIB, stage IIIC and stage IV. 
Stage I to IIA is the early stage and stage IIB to stage IIIC means that the cancer has ad-
vanced locally. Here we select only the four stages according to patient number. These
stages are described as follows: 
➢ Stage IA: Indicates that the tumor is small, invasive and has not spread to the
lymph nodes (T1,N0,M0).
➢ Stage IIA: Indicates the following results: there is no evidence of tumor in the
breast and it has not spread to the auxiliary lymph nodes (T0,N1,M0) / the tumor
is 20 mm or smaller and has spread to the auxiliary lymph nodes (T1,N1,M0)  /
the tumor is 20mm to 50mm and has not spread to the auxiliary lymph nodes or
to other parts of the body (T2,N0,M0).
➢ Stage IIB:  Indicates that the tumor is 20mm to 50mm and has spread to one to
three of the auxiliary lymph nodes (T2,N1,M0) / the tumor is larger than 50mm
and has not spread to the lymph nodes (T3,N0,M0).  
➢ Stage IIIA: Indicates any size of cancer or tumor larger than 50mm being
present and that they have spread to 4 to 9 auxiliary lymph nodes.
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2.4.2  SEER Staging System
The Surveillance, Epidemiology and End Results (SEER) is a more simplified system
and is used for cancer registry and health research. The system can be explained as fol-
lows: 
➢ Local Stage: It refers to the cancer identified in the breast and means that it
stays only in the identified area. (In the TNM system stage I and stage IIA are
equivalent to this stage.)   
➢ Regional Stage: In this stage cancer has spread to the surrounding tissues and /
or lymph nodes. Sometimes it is also being called as the advanced stage. (In the
TNM system stage IIA and stage IIIA together belong to this stage.)  
➢ Distant Stage: This stage refers to the cancer that has been spread to other parts
of the body or lymph nodes above the collar bone. (In the TNM system stages
IIIC and IV corresponds to this stage.) 
2.5 Principle Component Analysis(PCA)
Principle Component Analysis (PCA) is a multivariate data analysis technique that ana-
lyzes the data and that which elements are intercorrelated and dependent variable s. Pre-
sumably PCA is the most popular data dimension reduction technique used in many nu-
merical data analysis and feature selection. In [18] authors select features from micro ar-
ray data and apply hypothesis technique to the analysis of the breast cancer genes. The
goal of the PCA is to extract the important information of the data variables and to map
them into a similar observation called principle components. These principle compo-
nents are holding the maximum information of the data. 
“Mathematically,PCA depends upon eigen-deomposition of positive semi-definite matri-
ces and upon the singular value decomposition (SVD) of rectangular matrices“ [40].
Principle Component Analysis was described independently by many researchers
[41,42]. It was first invented by a British mathematician called Pearson [41]. Later on
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Hotelling [43] independently formalized it and termed it principle component analysis.
The idea of the PCA is to extract important information from the data set and express it
as a set of orthogonal variables. To get the principle component, PCA computes linear
combination of orthogonal variables. The first principle component is the largest vari -
ance. The second principle component is being calculated the same way as the first prin -
ciple component but with the largest variance under the constrain of orthogonal of the
first principle component. The third, fourth and all the other principle components are
being likewise computed. The most common application areas of the Principle Compo -
nent Analysis are data dimensionality reduction, lossy compression, feature extraction
and data visualization.   
Principle Component Analysis was defined in two different ways by Pearson and
Hotelling [41, 43]. First it can be defined as the orthogonal projection of the higher di-
mensional data onto a lower linear dimension called principle subspace where variance
of the projected data is maximized [43]. Secondly,  it can be defined as the linear projec-
tion where average projection error can be minimized [41]. The basic approach of prin-
ciple component analysis is very simple. The first step is to compute d dimensional
mean vector with dxd covariance matrix Σ for the whole data set. The second step is to
compute eigen vector e and eigen value λ. The third step is to sort the eigen values in
decreasing order. These eigen vectors with eigen values are the principle components.
The mathematical description of the PCA algorithm is explained below. 
.
Figure 2.5.1 Principle Component Analysis [44].              
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Consider a data set Xn where n = 1,2,3 …….N . Xn  is a euclidean variable with D di-
mension.  The dimension of Xn   to be reduced to M<D
Considering the projection of the data onto one dimensional space M, the direction of
the data can be defined by D dimensional unit vector u. where uTu = 1 and all the data
from D dimension is projected on the value of  uTxn . Where  xn   is sample mean 
                 x¯= 1
N∑n=1
N
xn   (1)
       The variance of the projected data is given by 
                 1
N∑n=1
N
{u1
T xn−u1
T x¯n}
2
=u1
T Su1  (2)     
  where S is the data covariance matrix is defined by 
                 S= 1
N∑n=1
N
(xn−x¯)( xn− x¯)
T   (3)
To maximize the projected variance uTSu  with respect to u1 ,under the constrain 
uu1 = 1 , a Lagrange multiplier λ1 is introduced.    
                 u1
T Su1+λ 1(1−u1
Tu1)    (4)
Taking the derivative with respect to u1 ,equal to zero, we get the equation below. The
equation says that u1 is the eigen vector of S.
                  Su1=λ 1u1    (5)
By left multiplying transpose of uT  in equation (5) we get      
                  u1
T Su1=λ1     (6)
The variance S will be maximum when u1 eigen vector with eigen value equals to λ1.
This eigen vector is called first principle. All the principal components can be computed
likewise by taking another direction of variance.  For n dimensional vector we can get n
different direction of projection eigen vector of eigen values λn.  
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where λ1  , λ2  , λ3……………λn         
 
2.6 Support Vector Machine
The Support Vector Machine (SVM) is a powerful machine learning technique for Two
group classification. The idea behind the SVM is that the non-linearly separable input
data is being transformed into high dimension feature space [32]. In this feature space a
linear decision surface is being constructed. SVM can be implemented for both separa-
ble and non separable input data. Linear SVM is being implemented where input data
can be linearly separable. The early SVM implementation was made by constructing op-
timal hyperplane between two separable input data. The Non-linear SVM is imple-
mented where the input data is non separable.
Given a training set of input ( xi , yi) , i=1,.... l , yi∈(−1,1) , xi∈Rd where x is input data
and y is class label. Let us consider some hyperplane which separates two classes: the
positive and the negative examples. The vector W is perpendicular to the plane in space.
The points x which lie on the plane satisfy W .x+b=0 .
The distance between origin and the plane is |b|/||W|| . Let the minimum distance be-
tween the hyperplanes which separates the positive or the negative example  be defined
as the margin. SVM algorithm simply finds the hyperplane with the largest margin. Let
us consider the training data that satisfies following constrains:    
 xi .W+b≥+1 for yi=+1  (1)
 xi .W+b<−1 for yi=−1  (2)       
combining one set of equalities we have 
yi(x i .W+b)−1≥0 for all i  (3)
The two hyperplanes are H1 : xi .W+b=1  and H2 : xi .W+b=−1 , the mar-
gin is simply 2/||W|| . The two hyperplanes are parallel to each other and no training
points fall in between those hyperplanes. Thus we can find the hyperplane that gives the
maximum margin by minimizing the ||W|2|
14
subject to constrain equation (3). 
    
 
Figure 2.6.1 left shows separable input data and right non-separable data in Support
Vector Machine[45].
Now let`s suppose that classes overlap in feature space so that data cannot be separable.
One way to find the hyperplanes is by letting grow the margin such a way that some
points can be located on the wrong side of the margin defined as slack variables
i , i=1... l . So the equation (3) can be written as 
yi(x i .W+b)≤1−i  (4)
>0  (5)
Φ()=∑
i=1
l
(i)  (6)
This is the usual way of applying the support vector machine for non separable data
[33]. Equation (6) describes the training error. To minimize the training error one can
simply remove those data from the training set [34]. For this case the Lagrange function
is 
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Lp=
1
2
||W|2|+∑
i=1
l
(i)−∑
i=1
l
 i [ yi(x i .W+b)−(1−)]−∑
i=1
l
iμ i  (7)
So far the support vector machine describes the linear boundary for classification. To
make it more flexible the support vector classifier uses nonlinear kernel functions.
There are three popular choices of kernel functions [34]: 
   dth- Degree polynomial:  (1+⟨x , x ´ ⟩)d
                         Radial basis:  exp(−ϒ (x−x ´)2)
                   Neural network : tanh (k1 ⟨ x , x ' ⟩+k2)
Figure2.6.1 left shows 4th degree polynomial kernel SVM and right radial basis kernel
SVM [34]. 
2.7  LIBSVM  
LIBSVM is a library for support vector machine. It can be used in many programming
languages like c, c++, python, R etc. LIBSVM supports three different learning
tasks[35] such as 
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1. Support vector classification(two class and multi class)
2. Support vector regression
3 One class support vector.    
LIBSVM works in two steps, first it is training the system to obtain the model and then
it is predicting the data using the model. 
  Main training sub-routine 
Two class and one class SVM
Various SVM formulations
Solving optimization problems
Figure 2.7.1 LIBSVM's code organization for training [35].
2.8 Gene Ontology
Gene Ontology project [36] provides controlled, structured vocabularies, gene ontology
(GO) and classifications that describes molecular and cellular biology, and which are
freely available for use in annotation of genes, gene products and sequences. GO de -
scribes the ontology of gene in three non-overlapping domains of molecular biology.
The vocabularies are organized based on three principles which are is-a and part-of-a re-
lationship with (each) other [37]. The three GO terms are: 
17
• Molecular function (MF) describes activities, such as catalytic or binding activi -
ties at the molecular level.
• Biological Process (BP) describes biological goals accomplished by one or more
biological functions. 
• Cellular component (CC) describes the location of sub cellular s tructures and
macromolecular complexes.   
In this project we use org.hs.eg.db package for gene mapping. 
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3. METHODOLOGY AND DATA
We collected the Level 3 RNA_Seq version 2 and the clinical data of BRCA cancer type
from the TCGA portal. We chose four different pathological tumor stages of cancer
from clinical information of all
Figure 3.1 Work flow diagram of the project. 
Find pathological stages
TCGA Data Portal
Clinical
 data
Barcode 
Output
  RNA_Seq V2 and 
MiRNA data
Download
Data Filtering 
Search 
from 
TCGA Save data 
GO Pathway analysis and resampling the data
Save 2 sets of data
Classify data
Output Results
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samples that is stage IA, IIA, IIB and IIIA (see Figure 3.2). The clinical data is filtered
according to the stages, Estrogen receptor PR status and her2 status for further process-
ing. We collected the corresponding barcodes of the patients according to the stages and
made a subset of RNA_Seq data. The data downloaded from TCGA portal .rsem. -
genes.results formate and rsem stands for RNA_Seq Expectation Maximization. The
gene data obtained from the TCGA portal is normalized data. We also collected non-
coding RNA seq data which is basically Micro RNA (miRNA_Seq) data. All the subsets
of data were placed in
 
Figure 3.2 Pathological stage of breast cancer patients of clinical data.
a matrix separately as noncoding and coding RNA. We labeled the data according to
stages such as 1,2,3 and 4 with respect to IA, IIA, IIB and IIIA. Finally we got 2 sets of
data with 962 samples of RNA_Seq and 252 samples of miRNA data (see Table 3.1). 
Table 3.1: Experimental data set 
   Data set Samples Features
RNA_Seq V2      962 20,531
miRNA      255 812
20
RNA_Seq data was being mapped according to the Gene Ontology so that we could
separate the significant genes from the large data sets. Those chosen genes are called
feature vectors.  We used org.Hs.eg.db library downloaded from the bioconductor repos-
itory. org.Hs.eg.GO which is an R object that maps entrenz IDs that are directly associ-
ated with GO identifiers. After mapping with GO db 18001 expressed genes were iden-
tified. RNA_Seq V2 data was divided into two parts, namely ProteinCoding RNA_Seq
and NonProteinCoding RNA_Seq data. Those genes which were mapped with GO data
base are called ProteinCoding RNA_Seq data and the ones which were not mapped with
GO Data base are named NonProteinCoding RNA_Seq data. After GO mapping, obtain
data sets were being given (see Table 3.2.).
Table 3.2: Experimental data set RNA_Seq V2 after GO analysis 
Data Sets Balanced class sam-
ples
Unbalanced class
Samples
Features
ProteinCoding
RNA_Seq
424 962 18001
NonProteinCoding
RNA_Seq
424 962 2240
Figure 3.3 shows clinical information about hormone receptor status that is being used
mostly in molecular based analysis. The positive or negative values of Estrogen-Recep -
tor(ER), Progesterone-Receptor(PR) and HER2 mean the presence or the absence of
ER, PR, and HER2. These three markers are being used to identify the molecular sub-
types of breast-cancer. From the figure it can be noticed that the number of triple nega -
tive of ER, PR and HER2 patients is around 200 which is known as basal-like breast-
cancer and it is very common in women with BRCA1 gene mutation. This type of can -
cer is also common in young African-American women. Another type of cancer is called
luminal B which is characterized by triple positive of ER, PR and HER2. The number of
triple positive patients is around 150. 
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Figure 3.3 Clinical information of estrogen progesterone and her 2 receptor status of
breast cancer. 
Data was sampled according to variance of genes. The histogram of log of variance of
three data sets are shown in Figure 3.4. We have extracted fea tures by more frequently
occurred variances for protein coding and non-coding RNA_seq and high variance for
micro RNA data. The feature selection was performed manually trying different ranges
of variances and then we selected the best feature.  
     Figure 3.4 histogram of log of variance of the data.
3.1 Performance measure 
There are four different classifications in machine learning area: binary, multi-class,
multi-level and hierarchical classification[38]. In binary classification input is classified
into one and only one class out of two non overlapping classes (C1 and C2). This is the
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most popular classification used in machine learning. Multi-class classification classi-
fies input data into one and only one class out of l non overlapping classes. Multi-level
classification classifies input data into several classes out of l non overlapping classes.
In hierarchical classification input is classified into one out of l classes, which are di -
vided into subclasses or subgroups of a superclass.        
Our approach was to use multi-class classification as gene data were to be classified into
four different subclasses or substages of breast cancer. There are two ways of perfor-
mance measurements: one is the macro averaging which is the average of the same mea-
sures of all the classes C1 ….Cj and the other one is the micro averaging sum which is
the sum of the cumulative True Positive (tp), True -negative (tr), False Positive(fp),
false Negative(fn) and the measure`s performance. 
Figure 3.1.1 Overview of binary classification(wikipedia).
3.2 Performance measure calculation for Multi-class prediction 
Let`s assume the number of the classes is denoted by l. 
Sensitivity: The ability of the test is to correctly identify those samples which belong  to
the test class. 
Sensi= tp
tp+ fn
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The Average per class effectiveness of the classifier to identify the class labels is 
∑
i
l
Sensi
l
Specificity: The ability of the test to correctly identify those samples does not belong to
the test class.
Speci= tn
fn+tn
The Average per class effectiveness of classifier to identify the class labels is 
∑
i
l
Speci
l
Accuracy: Accuracy can be measured by calculating the summation of the True Positive
over the whole data set. 
  ∑ tp
N
where tp is true positive and true negative respectively of C(1...c) classes. 
N is the number of the test samples. 
 Here in this project we calculated the standard error measure. The standard error is the
standard deviation of sampling distribution of the mean. The formula can be written as: 
σ= sd
√N
 
Where sd stands for the standard deviation of the original error of each class and N
stands for the test sample. σ is the mean standard error. The larger the sample size is the
smaller the standard error.  
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3.3  K- fold Cross Validation
Cross validation (also called model validation technique) is a testing method that tests
the classifiers accuracy. Cross validation is used to select the best classifier in some in-
dependent data set.
Figure 3.3.1  k-fold cross validation (wikipedia).
In the cross validation technique the whole data set is partitioned into k-sets: the classi -
fier is being tested on one part of the data set and the rest is used for training. There are
different types of cross validations. Here only k-fold cross validation will be discussed. 
   
Figure 3.3.2 Accuracy of different subsets of test data in 10 fold CV of Protein Coding
RNA_seq. 
In k-fold cross validation (see Figure 3.5), in the first round, the data is partitioned into
k fold and one fold is being kept for testing or validating the classifier. The  rest of the
data sets are used for training the classifier. To reduce the variability, multiple rounds of
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cross validation is being performed and the result is being averaged. Taking each accu -
racy of each fold or subset of test data and performing averaging on them makes the
classifier accuracy more accurate. Figure 3.6  shows the different accuracy values in dif -
ferent subsets of test data. Accuracy varies with respect to the subset of the test data. It
is clear from the bar graph that mean accuracy calculat ion reduces the variation of the
accuracy and gives accurate results for the classifier. K-fold cross validation technique
was used in this study to evaluate the prediction ability of the support vector machine
(SVM) method in the breast cancer gene data classification. Here different numbers of
cross folds were being used such as 4,5,6 to select the best number of folds. Perfor -
mance measures reported in this study are the averages of 4,5 and 6 estimates obtained
from 4,5 and 6 fold.
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4. RESULTS  AND DISCUSSION 
In this chapter we compare different substages of breast cancer prediction classifications
with different sets of RNA_seq data. The results are ordered according to the classifier
performance in different data sets. The results are discussed in different assumptions
such as balanced and unbalanced class labels and on the basis of how feature selection
improves the accuracy and overall performance. We have analyzed the data with the
help of two different breast cancer staging systems namely Surveillance, Epidemiology
and End Results (SEER) and Tumor, Node and metastasis (TNM). Before the classifica -
tion of the breast cancer into two different systems of staging we created two sets of
RNA_seq data(see Table 4.1, 4.2.1 and 4.2.2). Each data set was classified them based
on balanced class labels and unbalanced class labels. The balanced and unbalanced class
labels are defined as follows: 
•  Balanced class labels: Equal size of samples from each stage of breast cancer
genes were taken and we labeled them according to the stage name.
•  Unbalanced class labels: Unequal size of samples from each stage of breast can -
cer genes were taken and we labeled them according to the stage name.
The idea behind creating balanced and unbalanced class labels was to see the effect of
the classifier on equal and unequal sample sizes of data.  
4.1 SEER Staging System sub-stage Classification
The three different data sets protein coding RNA, non-coding RNA and miRNA were
classified according to the SEER staging system. It was investigated how the classifier
performs in different combinations of stages. In this study we performed the classifica -
tion task only for the primary and the regional stages. The four different substages of
data namely stage IA, IIA, IIB and IIIA were being divided into 2 sets:
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Table 4.1  created data sets with combination of different stages
Data Stage Sample number
Set 1 (Stage IA, Stage IIA)  and  (Stage IIB,
Stage IIIA)   
 962
Set 2 Stage IA and Stage IIB  396
 
4.1.1 Unbalanced class labels
The following tables below show the classification results of unequal class labels with
the sample size of 962 patients.  
Table 4.1.1.1  Summary of the results for the protein coding RNA_Seq data set1.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error (acc)
Sensitivity
(%)
Standard
Error (Sen-
sitivity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 58.67 0.0169 61.56 0.0255 55.48 0.0170
5 57.46 0.0044 59.14 0.0142 55.76 0.0154
6 56.16 0.0205 59.81 0.0176 52.25 0.0389
precision/recall Table
Fold precision Recall AF1
4 60.05 61.56 0.6076
5 59.14 59.14 0.5906
6 57.80 59.81 0.5858
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The Protein Coding RNA_Seq data Set 1 (see section 4.1) prediction performance (table
4.1.1) shows that accuracy, sensitivity and specificity varies vary little amount in diff er-
ent cross folds while standard error varies significantly from 4 fold to 5 fold cross vali-
dation. In 5 fold cross validation the classifier gives lower standard error, almost similar
accuracy, sensitivity and a good F1 score as well. 
Now if we consider only a small portion of the data (for instance stage IA and Stage IIB
as class 1 and class 2 respectively) (table 4.1.1.2) the performance differs from the table
4.1.1 significantly. In this prediction although sensitivity decreases 20%,  prediction ac-
curacy increases 10% together with 30% increment of Specificity. On the other hand
AF1 score decreases with precision and recall. 
Table 4.1.1.2  Summary of the results for the protein coding RNA_Seq data set 2. 
Sensitivity/Specificity Table 
Fold Accuracy(
%)
Standard
Error (acc)
Sensitivity
(%)
Standard Er-
ror (Sensi-
tivity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 71.18 0.0254 41.36 0.0944 81.83 0.0428
5 70.15 0.0310 34.72 0.0306 82.99 0.0188
6 69.09 0.0208 28.96 0.0423 84.08 0.0197
Precision /recall Table
Fold precision Precision Recall AF1
4 45.70 41.36 0.4196
5 42.58 34.72 0.3806
6 39.64 28.96 0.3275
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The tables (Table 4.1.1.3 and Table 4.1.1.4) indicate prediction performance of noncod-
ing data. By comparing results of the two tables for noncoding data we see that data set
1 gives overall better performance than data set 2 with 5 fold cross validation. In these
two tables both accuracy and sensitivity is around 5 % higher in data set 1 than data set
2. Both tables show good AF1 score.
In noncoding data set although accuracy and AF1 score are almost the same, sensitivity
is significantly better in data set 2 (table 4.1.4)  than in data set 1(table 4.1.3). As com -
pared to the protein coding data, overall prediction performance is better in noncoding
data because here accuracy, sensitivity and specificity are in almost equal range, ie. in
the range of 55% to 60%.  
Table 4.1.1.3 Summary of the results for the non-coding RNA_Seq data set 1.
Sensitivity/Specificity Table
Fold Accuracy(%
)
Standard
Error
(acc)  
Sensitivity
(%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard
Error
(Speci-
ficity)  
4 57.60 0.0240 57.35 0.0328 57.09 0.0659
5 61.08 0.0290 60.97 0.0598 60.20 0.0607
6 57.65 0.0222 60.52 0.0160 54.92 0.0394
precision/recall Table
Fold precision Recall AF1
4 58.13 57.35 0.5749
5 61.12 60.97 0.6046
6 53.11 60.52 0.5812
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Table 4.1.1.4 Summary of the results for the non-coding RNA_Seq data set 2.
Sensitivity/Specificity Table
Fold Accu-
racy(%)
Standard Er-
ror (acc)  
Sensitivity
(%)
Standard Er-
ror (Sensi-
tivity)  
Speci-
ficity(%)
Stan-
dard Er-
ror
(Speci-
ficity)  
4 55.32 0.02733 63.22 0.0326 47.09 0.0234
5 55.58 0.05205 56.94 0.0764 53.18 0.0497
6 54.90 0.02834 57.18 0.0461 53.52 0.0428
precision/recall Table
Fold precision Recall AF1
4 54.01 63.22 0.5796
5 54.85 56.94 0.5548
6 54.84 57.18 0.5533
On the other hand, with miRNA sub-stage class prediction gives better classification ac-
curacy and sensitivity than protein coding and non-coding RNA_seq. From table 4.1.5
the classification accuracy is the same all over cross fold while sensitivity and speci -
ficity varies 66% to 70%  and 44% to 47% respectively. For the data set 2 with less
samples miRNA class prediction performance is better than for data set 1. Table 4.1.1.6
shows that applying the cross fold has no significant effect on the class prediction model
but using the data set 2 has a significant effect on accuracy, sensitivity and AF1 score.
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Table 4.1.1.5  Summary of the results for the miRNA_Seq data set 1. 
Sensitivity/Specificity Table 
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 57.62 0.0366 66.60 0.0500 47.50 0.0629
5 57.17 0.0363 67.50 0.0439 49.83 0.1055
6 57.20 0.0412 70.93 0.0628 44.01 0.0630
precision/recall Table
Fold precision Recall AF1
4 57.37 66.60 0.6151
5 60.37 67.50 0.6118
6 57.23 70.93 0.6248
32
Table 4.1.16  Summary of the results for the miRNA_Seq data set 2.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 63.60 0.0233 82.38 0.0315 35.95 0.0541
5 62.94 0.0375 83.47 0.0534 30.00 0.0670
6 63.96 0.0436 81.04 0.0578 35.99 0.0588
precision/recall Table
Fold precision Recall AF1
4 66.38 82.38 0.7313
5 64.49 83.47 0.7249
6 65.63 81.04 0.7215
4.1.2 Balanced class labels
In this section we evaluated the classifier performance in a balanced class labeled data.
Here we used total four class labels with 424 samples each of which consists of 106
numbers of samples. The class prediction results of equal size of samples of different
stages are listed below. In Table 4.1.2.1 for protein coding data set 1 (see Table 4.1) the
accuracy, sensitivity, specificity and AF1 score are around the same values for all num -
bers of the cross fold. 
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Table 4.1.2.1: Summary of the results for the protein coding RNA_Seq data set1.
Sensitivity/Specificity Table
Fold Accuracy(%) Standard
Error (acc)
Sensitivity
(%)
Standard
Error (Sen-
sitivity)  
Speci-
ficity(%)
Standard
Error
(Speci-
ficity)  
4 56.42 0.0169 55.58 0.0315 57.53 0.01069
5 55.41 0.0221 56.65 0.0208 54.18 0.03561
6 55.55 0.0308 56.84 0.0475 53.38 0.01847
precision/recall Table
Fold precision Recall AF1
4 56.45 55.58 0.5587
5 55.46 56.65 0.5596
6 54.03 56.84 0.5539
The results for data set 2 are summarized in Table 4.1.2.2 in which the four fold cross
validation gives a little bit better accuracy, sensitivity and higher AF1 scores than other
cross fold numbers. Although we used the same features for the class prediction, the
number of the training data does not have a significant effect on the classification re-
sults.
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Table 4.1.2.2: Summary of the results for the protein coding RNA_Seq data set2.
Sensitivity/Specificity Table
Fold Accu-
racy(%)
Standard
Error (acc)
Sensitivity
(%)
Standard Error
(Sensitivity)  
Speci-
ficity(%)
Standard
Error
(Speci-
ficity)  
4 59.06 0.0378 64.38 0.0599 53.80 0.0251
5 56.05 0.3898 62.11 0.0594 51.24 0.0394
6 56.75 0.0147 58.84 0.0349 55.78 0.04583
precision/recall Table
Fold precision Recall AF1
4 57.71 64.38 0.6075
5 56.27 62.11 0.5839
6 56.52 58.84 0.5690
From the tables (table 4.1.2.3 and table 4.1.2.4) it is clear that accuracy and AF1 of both
data sets are around 60% while in the protein coding it was at a lower range. The non-
coding data has a better performance as accuracy, sensitivity and specificity are at a
similar range, i.e. around 60 % which is a little bit higher than for the protein coding
RNA_seq data.
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Table 4.1.2.3: Summary of the results for the non-coding RNA_Seq data set1.
Sensitivity/Specificity Table
Fold Accu-
racy(%)
Standard
Error (acc)
Sensitiv-
ity (%)
Standard
Error (Sen-
sitivity)  
Specificity(%
)
Standard Er-
ror (Speci-
ficity)  
4 57.60 0.0240 57.35 0.0328 57.09 0.0659
5 61.08 0.0290 60.97 0.0598 60.20 0.0607
6 57.65 0.0222 60.52 0.0160 54.92 0.0394
precision/recall Table
Fold precision Recall AF1
4 58.13 57.35 0.5749
5 61.12 60.97 0.6046
6  53.11 60.52 0.5812
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Table 4.1.2.4: Summary of the results for the non-coding RNA_Seq data set2.
Sensitivity/Specificity Table 
Fold Accu-
racy(%)
Standard Er-
ror (acc)  
Sensitivity
(%)
Standard
Error
(Sensitiv-
ity)  
Speci-
ficity(%)
Standard
Error
(Speci-
ficity)  
4 55.32 0.02733 63.22 0.0326 47.09 0.0234
5 55.58 0.05205 56.94 0.0764 53.18 0.0497
6 54.90 0.02834 57.18 0.0461 53.52 0.0428
precision/recall Table
Fold precision Recall AF1
4 54.01 63.22 0.5796
5 54.85 56.94 0.5548
6 54.84 57.18 0.5533
4.1.3  Principle Component Analysis (PCA)
To reduce the high dimension of feature vector we applied the principle component
analysis (PCA) to see the effect of the model on breast cancer data. The PCA was ap-
plied on the data set 1 (see Table 4.1) for the protein coding, non-coding RNA_Seq and
the whole miRNA data. Only the first 20 PCA was taken as a feature with 5 fold cross
validation for both balanced and unbalanced class label data. The performance result for
the class prediction model is summarized in table 4.1.3. From the table below it can be
stated that the principle component has a significant effect on accuracy, sensitivity and
AF1 on protein coding for both balanced and unbalanced data sets. On the other hand
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we want to emphasize that it does not have a significant effect on non-coding and
miRNA data sets. 
Table 4.1.3: Summary of the results of PCA for all the data set.
 x %  Balanced Levels Unbalanced Levels
PCoding Non-cod-
ing
miRNA PCoding Non-cod-
ing
miRNA
Accuracy 65.47 59.52 47.72 66.66 64.61 54.47
Sensitivity 70.04 71.42 70.00 74.45 73.91 79.42
Specificity 60.00 47.61 29.16 56.75 50.81 25.00
precision 65.95 57.42 45.16 68.62 63.21 56.54
Recall 70.04 71.42 70.00 74.46 73.91 79.42
F1 Score
%
68.13 63.82 54.90 71.42 70.51 65.85
4.2 TNM Staging System sub-stage Classification
The following results depict the performance assessment of the tumor, the node and the
metastasis system of staging in breast cancer classification. Unlike Surveillance, Epi-
demiology and End Results(SEER) 
staging system, TNM staging classification is performed using multiple class classifica -
tion. The performance measure is averaged per class basis. Likewise, SEER classifica-
tion data set is divided into different sets with different combinations of stages. The best
two sets (See table 4.2) are selected for the 
assessment of the classifier. The prediction results for both the balanced and unbalanced
class labeled data are presented below. 
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Table 4.2.1: created data sets with combination of different stages of RNA_seq protein
coding and non-coding data
Data Stage Number of samples
Set 1 Stage IA, Stage IIA and Stage IIIA 672
Set 2 Stage IA, Stage IIA, Stage IIB and Stage
IIIA
962
Table 4.2.2: created data sets with combination of different stages of miRNA data
Data Stage Number of samples
Set 1 Stage IIA, Stage IIB and Stage IIIA 241
Set 2 Stage IA, Stage IIA, Stage IIB and Stage
IIIA
255
4.2.1 Unbalanced class
The total sample size is 962 for unbalanced data set. Class prediction results for protein
coding RNA_Seq data are presented below. From the table (Table 4.2.1.1 and Table
4.2.1.1) it is evident that accuracy improves better in data set 1 than data set 2 but sensi-
tivity and AF1 score do not show satisfactory results. The classifier cannot detect
around 70% of the class samples perfectly on the other hand it can reject 66% of the
samples that do not belongs to the target class. As an important finding of this study we
have observed that by selecting classes including stage IIB we receive a large amount of
false alarms. 
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Table 4.2.1.1: Summary of the results for the protein coding RNA_Seq data set 1.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 58.37 0.0145 33.24 0.0008 66.59 0.0006
5 58.30 0.0221 33.34 0.0000 66.66 0.0000
6 58.63 0.0110 33.34 0.0000 66.66 0.0000
precision/recall Table
Fold precision Recall AF1
4 19.56 33.24 0.2464
5 19.43 33.34 0.2452
6 19.54 33.34 0.2455
Similar performance to that of the protein coding RNA_Seq has been noticed for
Non_coding RNA_Seq data. Table 4.2.1.3 and Table 4.2.1.4 show that accuracy, sensi -
tivity and AF1 score remains the same even though the training data increases. In data
set 2 specificity increases 10% more than in data set 1, while accuracy and sensitivity in
data set 1 increases significantly more than in data set 2.
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Table 4.2.1.2: Summary of the results for the non-coding RNA_Seq data set2.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 42.77 0.022 27.31 0.0063 76.25 0.0034
5 43.15 0.014 27.30 0.0028 76.36 0.0019
6 42.18 0.016 26.73 0.0058 76.08 0.0030
precision/recall Table
Fold precision Recall AF1
4 19.82 27.31 0.2203
5 21,03 27,30 0.2373
6 20.05 26.73 0.2283
Table 4.2.1.3: Summary of the results for the non-coding RNA_Seq data set1.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 58.52 0.0125 33.34 0.000 66.77 0.0010
5 58.46 0.0251 33.34 0.000 66.66 0.000
6 58.63 0.0110 33.34 0.000 66.66 0.000
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precision/recall Table
Fold precision Recall AF1
4 19.56 33.34 0.2464
5 19.48 33.34 0.2455
6 19.54 33.34 0.2455
Table 4.2.1.4: Summary of the results for the non-coding RNA_Seq data set 2.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 42.36 0.0062 26.74 0.0036 76.02 0.0018
5 42.03 0.0200 26.82 0.0048 76.08 0.0028
6 41.98 0.0126 26.59 0.0063 75.90 0.0035
precision/recall Table
Fold precision Recall AF1
4 20.59 26.74 0.232
5 19.74 26.82 0.227
6 20.83 26.59 0.232
Micro RNA data set is divided into two different sets(see Table 4.2.2). The performance
of the class prediction using data set 1 and data set 2 are listed in Table 4.2.1.5 and Ta-
ble 4.2.1.5. It is evident from the table that the size of the training data effects on perfor -
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mance is being measured in miRNA data; for 5 fold cross validation accuracy increases
5% more than in the case of 4 and 6 fold cross validation.
Table 4.2.1.5: Summary of the results for the miRNA_Seq data set 1.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 49.77 0.0221 37.80 0.0086 69.82 0.0074
5 54.10 0.0266 41.61 0.0173 71.64 0.0103
6 51.80 0.0351 39.71 0.0209 71.06 0.0152
precision/recall Table
Fold precision Recall AF1
4 39.61 37.80 0.3778
5 43.62 41.61 0.4189
6 35.67 39.71 0.3753
Table 4.2.1.6: Summary of the results for the miRNA_Seq data set 2.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 45.51 0.0610 26.71 0.0182 76.39 0.0117
5 48.25 0.0307 28.74 0.0169 77.46 0.0083
6 44.32 0.0478 27.08 0.0195 76.24 0.0122
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precision/recall Table
Fold precision Recall AF1
4 29.61 26.71 0.2729
5 24.07 28.74 0.2609
6 29.05 27.08 0.2763
4.2.2 Balanced class labels
In this section we will discuss about the effect of the classifier on equal size of class la -
bels. Here only protein coding RNA_Seq and non-coding RNA_Seq will be discussed.
From the protein coding and non-coding data set class labels are extracted in equal
sizes. Each class contains 106 samples. Two different data sets are created as it can be
seen from Table 4.2.1. The first data set contains three stages: Stage IA, Stage IIA and
Stage IIIA with the total number of sample size of 318. 
The second set of data contains all the stages with 424 samples (see Table 4.2.2). In the
protein coding data set training size does not have effect on the performance measure
unlike the unbalanced data set that was previously discussed. On the other hand the
overall performance in the class prediction differs significantly between the two data
sets. 
The data set 1 has a better performance than the data set 2(see Table 4.2.21 and Table
4.2.2.1) 
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Table 4.2.2.1: Summary of the results for the protein coding RNA_Seq data set 1.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 38.55 0.0228 40.05 0.0152 69.94 0.0091
5 40.45 0.0230 40.93 0.0201 69.77 0.0096
6 38.69 0.0230 40.08 0.0201 69.77 0.0091
precision/recall Table
Fold precision Recall AF1
4 40.27 40.05 0.4015
5 40.27 40.93 0.4015
6 39.99 40.08 0.4001
From the tables(Table 4.2.2.1 and Table 4.2.2.2) it is obvious that the classifier cannot
classify breast cancer sub-stages perfectly in the TNM staging system. Both data sets
give poor performance. 
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Table 4.2.2.2: Summary of the results for the protein coding RNA_Seq data set 2.
Sensitivity/Specificity Table
Fold Accu-
racy(%)
Standard
Error
(acc)  
Sensitivity
(%)
Standard
Error
(sensitiv-
ity)  
Specificity(%) Standard Er-
ror (Speci-
ficity)  
4 24.81 0.0281 28.25 0.0276 75.88 0.0077
5 29.73 0.0225 30.32 0.0220 76.77 0.0066
6 29.16 0.0174 30.19 0.0214 76.78 0.0064
precision/recall Table
Fold precision Recall AF1
4 28.06 33.63 0.2936
5 31.62 30.32 0.3063
6 30.94 30.19 0.3039
The model was afterwards tested on non-coding RNA_Seq data. The classifier’s perfor-
mance is listed in the table (Table 4.2.2.3 and Table 4.2.24) with different cross fold
numbers. From the tables (Table 4.2.2.3 and Table 4.2.24) the classifier’s performance
looks similar to that of the protein coding RNA (see Table 4.2.21 and Table 4.2.2.1).  
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Table 4.2.2.3: Summary of the results for the non-coding RNA_Seq data set 1.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 38.59 0.0428 39.03 0.0373 69.53 0.0189
5 37.36 0.0134 37.11 0.0087 68.52 0.0043
6 35.30 0.0199 35.86 0.0174 68.18 0.0080
precision/recall Table
Fold precision Recall AF1
4 38.02 39.03 0.3850
5 37.62 37.11 0-3732
6 36.43 35.86 0.3613
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Table 4.2.2.4: Summary of the results for the non-coding RNA_Seq data set 2.
Sensitivity/Specificity Table
Fold Accuracy(
%)
Standard
Error
(acc)  
Sensitiv-
ity (%)
Standard Er-
ror (Sensitiv-
ity)  
Speci-
ficity(%)
Standard Er-
ror (Speci-
ficity)  
4 24.82 0.0045 25.58 0.0063 75.72 0.0014
5 26.64 0.0196 28.65 0.0217 76.09 0.0063
6 25.89 0.0255 27.55 0.0270 75.81 0.0078
 precision/recall Table
Fold precision Recall AF1
4 24.50 25.58 0.2502
5 26.09 28.65 0.2724
6 27.88 27.55 0.2744
4.2.3 Principle Component Analysis (PCA)
Application of principle components on feature vectors of both protein coding and non-
coding RNA_seq in a balanced class label and PCA on protein coding RNA_Seq, non-
coding RNA_Seq and miRNA in an unbalanced class label are listed in the Table 4.2.3
with 5 fold cross validation and the first 20 principle components. From the Table 4.2.3
it is quite clear that the principle component cannot increase the performance of the
class prediction of the TNM staging system.   
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Table 4.2.3: Summary of the results of PCA for all the data set.
 Balanced Levels Unbalanced  Levels
PCoding Non-coding PCoding Non-cod-
ing
miRNA
Accuracy 26.40 28.08 41.97 41.59 46.36
Sensitivity 28.18 28.61 27.00 26.77 27.44
Specificity 76.05 76.27 76.07 76.07 76.65
precision 26.97 29.68 23.07 20.41 27.10
Recall 28.18 28.61 27.00 26.77 27.44
F1 Score
%
0.275 0.290 0.245 0.231 0.264
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4.3 Discussion on Results
Apart from creating different data sets with feature selection, the whole data set was
used to classify the SEER staging system and TNM staging system with different cross
fold. 
Protein Coding RNA_Seq data
Non_coding RNA_Seq data
Figure 4.3.1 ROC of SEER sub-stage classification. 
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The Figure 4.3.1 summarizes the performance of the classifier of the SEER sub-stage
classification where Area Under the Curve (AUC) and accuracy are being considered as
performance metrics. It is clear from the figure that taking into account only two stages
(data set 1)  gives a better performance than if we consider four stages (data set 2) for all
the data sets. 
Figure 4.3.2 ROC of TNM sub-stage classification.
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The classification results of the both protein coding and the non-coding RNA data sets
show increase in accuracy and AUC in data set 2 as compared to data set 1(see Table
4.1). Both the protein coding and the non-coding RNA show poor AUC in the classify-
ing data set 1. Here the classifier plays a better role in the miRNA sub-stage classifica -
tion. In both data set 1 and data set 2 AUC is around 70% and accuracy is around 60%.  
In TNM sub-stage classification system the classifier performance reduced significantly.
Figure 4.3.2 shows the performance of the classifier for all the data sets(see Table 4.2.1
and Table 4.2.2). In the protein coding data, the accuracy is higher in the classification
of the three different stages(data set 1) than in the classification of the four stages(data
set 2) whereas AUC is lower. In the case of the non-coding RNA both AUC and accu-
racy show higher values in data set 1 than in data set 2. The sample size did not have
signifiant effect on the performance of the protein coding and the non-coding data. In
the case of the miRNA data classification, both accuracy and AUC improves from data
set 2 to data set 1.         
From the above discussion we see that if the number of the stages reduced then the clas-
sification performance improves despite the fact that the sample size reduced. Stage IIA 
and IIB have quite similar statistical distributions. This might be a reason why the clas-
sifier is more likely to give false predictions than true predictions. The results are being 
presented above only with the best features that we studied so far. 
From the experiments we have performed the following conclusions can be drawn:
➢ The model cannot predict well the cancer sub-stage in the TNM staging system.
➢ The model has no effect on the sample size variation in the TNM system.
➢ The model can predict the cancer stages with satisfactory results in the SEER
staging system using the protein coding RNA_Seq and the non-coding
RNA_Seq data. 
➢ The model can predict the stage of cancer with good result using the
miRNA_Seq data. 
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➢ The model has no significant effect of principle component analysis on the
miRNA in either of the staging systems.
➢ Further study on the miRNA by selecting the most significant genes may predict
the cancer stages with a better result.    
The reason is unknown why the Principle Component Analysis can give a better perfor-
mance with the protein coding genes in the SEER staging system but has no signifiant
effect on the non-coding genes(see section 4.1.3). With the help of the above investiga-
tion we have identified the 11 most significant miRNA genes that gives the classifier an
output of more than 90% sensitivity, around 60% accuracy and an AUC of 0.72 in the
SEER staging system (see Figure 4.3.1).
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5. CONCLUSION
In this study we have investigated and compared the prediction performance of sub-
stage classification of breast cancer in the SEER and the TNM staging system selecting
from 10 to more than a thousand genes as a feature. We have identified that miRNA
with the 11 most significant genes can offer a better prediction than the protein coding
and non-coding genes. In the two data sets (see table 4.1) in unbalanced class labels and
balanced class labels accuracy varies from 56% to 58% in data set 1 and 56% to 70% in
dataset 2 for protein coding genes. On the other hand the non-coding genes have no
variation in accuracy for balanced and unbalanced class labels. For the miRNA data we
have applied only unbalanced class labels due to the small amount of available sample
size in stage IA. A little variation in accuracy is present- from 57% to 62% for the 2 dif-
ferent data sets. Furthermore, we have also investigated the changes in the performance
metrics using four stages.  We have focused our attention on the best performing combi-
nation after checking the performance of all the possible combinations of two stages out
of the four. The model behaves significantly different ways in the two different ap-
proaches. For the unbalanced class label accuracy varies 56% to 70%  for the protein
coding data while in the balanced class label it has no significant variation. In fact bal -
ancing the class labels does not give any significant improvements on the accuracy of
the model for predicting the breast cancer sub-stage classification. However, the predic-
tion model achieves 15% better accuracy by selecting only two stages out of the four
stages. Moreover, miRNA performs more desirably with the accuracy of 62% and with
an AUC of 0.72 which is a sign of a good classifier. 
In addition, using the PCA model gives a better accuracy and sensitivity for protein cod -
ing and a little change in the non-coding genes but no significant accuracy gain on mi -
cro RNA genes. A few researchers have used PCA for micro array data to differentiate
between tumor and non tumor genes [18]. The authors implement statistical hypothesis
by selecting features using principal component analysis. In our study we selected fea-
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tures using variance of genes in different stages. Many researchers have predicted breast
cancer on a molecular subtype basis [19,22]. 
Most of the subtype classification is performed by statistical analysis, while in our study
we have used the machine learning method support vector machine (SVM) to predict
breast cancer sub-stages in two different staging systems namely in SEER (Surveillance,
epidemiology and END Results) and in TNM (Tumor, Node and Metastasis). The micro
RNA is identified as an indicator of breast cancer progression and as a biomarker for
sub-stage classification [21,22]. In our study we have also found that miRNA is the key
gene for the breast cancer progression and sub-stage classification. 
Feature selection was performed manually by checking beans of histogram of variance
of all the genes and we fed the data to our model to predict sub-stages. After a lot of trial
and error method we ended up with a certain range of beans of histogram of log of vari-
ances of genes that gives best performance with the SVM method. The feature dimen-
sion was high enough to give a perfect prediction. Then we applied the principle com-
ponent analysis to reduce the feature dimension. Application of the PCA shows insignif -
icant improvements in protein coding and non-coding data but no effect on miRNA. In
fact PCA works on high dimensional data and they should be intercorrelated. In our
study after the feature selection the miRNA feature vector was lower than the sample
size. So by definition we cannot state that miRNA is high dimensional data. Protein
coding and non-coding data has more than 7000 features and not all of them correlated.
This may be one of the reasons why the principle component did not work on the
miRNA. 
Based on our work it can be concluded that for he TNM staging system merely the us -
age of the support vector machine is not sufficient enough but a more robust technique
is being needed. SVM with PCA can be effectively used as a model providing possible
further insights into the protein coding data analysis in SEER staging system in the fu-
ture and SVM can be utilized in itself for the miRNA to predict class labels for the
SEER staging system. 
We used libsvm package for svm computation and prcomp library was used to compute
pca; pROC, e1071 and caret for ROC, SVM and confusion matrix were used respec-
tively. With corei5 and 8 GB RAM, the analysis of the three different data the computer
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took 0.5 min to 8 mins depending on the size of the data and the numbers of cross fold.
This speed is pretty fast as we have not worked with any clusters.    
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